Physician profile
Amanda Eckersley
NPI 1447802418
$2,050.70
in general payments reported to CMS, 2019-2025
23 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.90 · 2022: $212 · 2024: $352 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.84 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $246.22 | 2025 | Darzalex, Talvey, Tecvayli |
| Janssen Biotech, INC. | $191.39 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $191.06 | 2022-2025 | Lynparza |
| Glaxosmithkline, LLC. | $176.95 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $157.72 | 2025 | Imdelltra (Amg757) |
| Tempus Ai, INC | $130.90 | 2025 | Xt Cdx |
| Abbvie INC. | $128.78 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.61 | 2022-2025 | Opdivo |
| Eisai INC. | $102.32 | 2024 | |
| Incyte Corporation | $90.44 | 2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $76.91 | 2025 | |
| Adaptive Biotechnologies Corporation | $69.25 | 2025 | Clonoseq |
| Pfizer INC. | $69.00 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.16 | 2024-2025 | Keytruda |
| Tersera Therapeutics LLC | $55.40 | 2025 | Xermelo, Zoladex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $44.87 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $29.35 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.62 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $26.38 | 2025 | Brukinsa |
| Genentech, INC. | $19.35 | 2024 | Columvi, Venclexta, Lunsumio |
| Iovance Biotherapeutics, INC. | $17.66 | 2025 | Amtagvi |
| Astellas Pharma US INC | $17.46 | 2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $15.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Eckersley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.